Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
When the beta blocker nebivolol was approved by the FDA in 2007, we advised readers not to use the drug until 2015, in accordance with our seven-year rule. Find out why we now have designated nebivolol as Limited Use and whether it is the right choice for treating hypertension.
The article discusses possible breathing risks of nebivolol (BYSTOLIC)and how other, older drugs — just as effective as this relatively new high blood pressure drug — are preferred because more is known about their risks.
This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.
The article lists 57 different drugs that can cause dementia if used. This can be even more problematic if more than one of these drugs is being taken. These drugs are only one class of drugs that can cause mental deterioration and next month's issue will discuss additional drugs that can also impair thinking.
Twenty different NSAIDS (nonsteroidal antiinflammatory drugs) are listed in this article that can adversely affect your blood pressure control. The article discusses the way in which this happens and what you can do about it.
Although the FDA medical officer in charge of reviewing ranolazine recommended that ranolazine's professional product labeling display a black box warning about potential disruption in the heart's electrical cycle, the drug does not have a black box warning.
Assume that any new symptom you develop after starting a new drug may be caused by the drug. If you develop a new symptom after starting atorvastatin or other statins (such as nightmares), report it to your doctor. The drug may be responsible.
You should check the list of drugs that can cause loss of bladder control before starting drug treatment for this condition. You may be able to change from a drug that causes loss of bladder control to a drug that does not or alter the dose. This may be enough to solve the problem.
Escitalopram (LEXAPRO) was approved by the Food and Drug Administration (FDA) in August 2002 and brings to six the number of selective serotonin reuptake inhibitor (SSRI) antidepressants now on the market in the U.S. The primary purpose for developing escitalopram appears to be nothing more than a strategy to protect sales as citalopram nears the end of its patent protection. In the long run, escitalopram will cause economic harm to individuals and the healthcare system.